Compare HCA Health Inc (HCA) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs MobilEye Global Inc — how do they compare? HCA Health Inc trades at $450.18 (market cap $96.35B), while MobilEye Global Inc trades at $7.12 (market cap $6.00B). The key difference: HCA Health Inc is far larger — about 16.1× MobilEye Global Inc's market cap, and HCA Health Inc pays a 0.7% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and MobilEye Global Inc for 15 Days on average.
| HCA | MBLY | |
|---|---|---|
Market Cap | $96.35B | $6.00B |
Volume | 1,079,453 | 7,007,849 |
Sector | Health | Consumer Cyclical |
52-Week High | $545.13 | $15.42 |
52-Week Low | $361.32 | $6.56 |
Typical Hold Time | 76 Days | 15 Days |
Enterprise Value | $146.88B | $4.56B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $449.47, up 2.35% with bullish technical indicators and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $7.59 exceeding expectations, while revenue growth continues from $75.6B in 2025 to projected $78.0B in 2026. Analyst consensus remains strongly positive with 63% buy ratings and $461.12 price target, though legal investigations present headwinds.
The outlook remains favorable with solid patient demand and operational efficiency driving growth, though investors should monitor ongoing legal investigations and debt levels. Valuation appears reasonable with P/E of 14.92 and EV/EBITDA of 9.26, while technical support at $440 provides near-term stability.
Mobileye Global (MBLY) trades at $7.11, down 0.56% on the day, with a bearish technical outlook but mixed fundamental signals. The stock shows negative profitability with a net income margin of -201.49% for 2026, yet revenue grew to $2.0 billion. Recent earnings beats in Q1 and Q2 2026 contrast with a Q4 2025 miss, while analyst consensus is a 'Buy' with a $10.83 price target. News highlights ADAS momentum and a robotaxi strategy expansion, but the stock faces significant cash flow volatility.
The outlook for MBLY is cautious; while analyst optimism and revenue growth provide upside potential, persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of autonomous driving programs, but shareholders face volatility from negative earnings and high valuation multiples like EV/EBITDA of 32.34.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
